Company
NXI Therapeutics AG
Incorporated
May 2021
Headquarter
Basel
Support
Novel Therapy for Autoimmunity and Organ Transplantation.
NXI Therapeutics intends to commence operations with screening and preclinical development of compounds that interfere with coronin 1-dependent T cell activation in autoimmune diseases and organ transplantation. A biomarker and a diagnostic program targeted towards the development of assay systems to analyse the effectiveness of the therapy and naïve T cell populations for use in patients undergoing immunosuppression is optional.
